Factors related to the therapeutic efficacy of 131 Ⅰ in Graves' disease
10.3760/cma.j.issn.1000-6699.2011.12.004
- VernacularTitle:影响Graves病131Ⅰ疗效的因素分析
- Author:
Xinjian ZHOU
;
Yuan ZHAO
;
Yulian ZHU
;
Yingchun ZHU
;
Lai WEI
- Publication Type:Journal Article
- Keywords:
Graves' disease;
Iodine radioisotopes;
Radionuclide imaging;
Ultrasonography;
Thyroid weight
- From:
Chinese Journal of Endocrinology and Metabolism
2011;27(12):975-978
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo explore the efficacy of 131 Ⅰ treatment in Graves' disease,and to analyze the related factors.MethodIn 87 patients with Graves' disease,thyroid uptake ratio( TUR ) and its effective half-life(EHL) were compared before and after 131 Ⅰ treatment.The weight of thyroid gland was evaluated with radio-imaging and type B ultrasonography.ResultThe dose of 131 Ⅰ was ( 185.2 ± 148.0 ) MBq.The TUR of tracer dose and therapeutic 131 Ⅰ dose were 76.5 % ±8.2% and 73.3 % ±9.0% ( t =2.451,P =0.008 ).The EHL were ( 5.2±0.7 ) and ( 5.0 ±0.8 )days,respectively ( t =1.998,P =0.023 ).After followe-up of ( 57.0 ±26.3 ) months,49 patients ( 56.3 % ) became euthyroid,14 ( 16.1% )manifested delayed hypothyroidism,and 24 (27.6%)remained in hyperthyroidism.Thyroid autoantibodies were found in 34.5% patients,of whom,the incidence of hypothyroidism was higher in patients with positive autoantibodies than those with negative ones (30.0% vs 8.8%,x2 =6.560,P =0.009 ).ConclusionBoth TUR and EHL of therapeutic doses of 131 Ⅰ are lower than the tracer doses.Positive thyroid autoantibodies may affect the outcome of the 131 Ⅰ treatment.